Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Medication nonadherence among South American patients with schizophrenia.

Caqueo-Urízar A, Urzúa A, Fond G, Boyer L.

Patient Prefer Adherence. 2017 Oct 6;11:1737-1744. doi: 10.2147/PPA.S144961. eCollection 2017.

2.

Association between Medication Adherence and Duration of Outpatient Treatment in Patients with Schizophrenia.

Tarutani S, Kikuyama H, Ohta M, Kanazawa T, Okamura T, Yoneda H.

Psychiatry Investig. 2016 Jul;13(4):413-9. doi: 10.4306/pi.2016.13.4.413. Epub 2016 Jul 25.

3.

Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.

Baylé FJ, Tessier A, Bouju S, Misdrahi D.

Patient Prefer Adherence. 2015 Sep 16;9:1333-41. doi: 10.2147/PPA.S89748. eCollection 2015.

4.
5.

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection.

Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H.

Neuropsychiatr Dis Treat. 2014 Jun 20;10:1125-31. doi: 10.2147/NDT.S61409. eCollection 2014.

6.

Medication adherence in schizophrenia.

Acosta FJ, Hernández JL, Pereira J, Herrera J, Rodríguez CJ.

World J Psychiatry. 2012 Oct 22;2(5):74-82. doi: 10.5498/wjp.v2.i5.74. Review.

7.
8.

Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder.

Medina E, Salvà J, Ampudia R, Maurino J, Larumbe J.

Patient Prefer Adherence. 2012;6:623-9. doi: 10.2147/PPA.S34345. Epub 2012 Aug 29.

9.

Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment.

McGorry PD, Cocks J, Power P, Burnett P, Harrigan S, Lambert T.

Schizophr Res Treatment. 2011;2011:631690. doi: 10.1155/2011/631690. Epub 2011 Feb 7.

10.

Adherence to medication for the treatment of psychosis: rates and risk factors in an Ethiopian population.

Alene M, Wiese MD, Angamo MT, Bajorek BV, Yesuf EA, Wabe NT.

BMC Clin Pharmacol. 2012 Jun 18;12:10. doi: 10.1186/1472-6904-12-10.

12.

Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia.

Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR.

Am J Psychiatry. 2011 Mar;168(3):286-92. doi: 10.1176/appi.ajp.2010.09010087. Epub 2011 Jan 4.

13.

Prevention of schizophrenia relapse with extended release quetiapine fumarate dosed once daily: a randomized, placebo-controlled trial in clinically stable patients.

Peuskens J, Trivedi J, Malyarov S, Brecher M, Svensson O, Miller F, Persson I, Meulien D.

Psychiatry (Edgmont). 2007 Nov;4(11):34-50.

14.

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.

Treur M, Heeg B, Möller HJ, Schmeding A, van Hout B.

BMC Health Serv Res. 2009 Feb 18;9:32. doi: 10.1186/1472-6963-9-32.

15.

Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia.

Sapra M, Vahia IV, Reyes PN, Ramirez P, Cohen CI.

Schizophr Res. 2008 Dec;106(2-3):348-55. doi: 10.1016/j.schres.2008.09.004. Epub 2008 Oct 11.

16.

Factors influencing adherence in children and adolescents treated with antipsychotics or antidepressants.

Yazdi K, Unterlass G, Kemmler G, Kralovec K, Aichhorn W.

Prim Care Companion J Clin Psychiatry. 2008;10(2):160-1. No abstract available.

Supplemental Content

Support Center